国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Health

Roche's VENTANA PD-L1 Assay gains CE label expansion to inform treatment

chinadaily.com.cn | Updated: 2017-06-06 18:52
Share
Share - WeChat

Roche announced the launch of the VENTANA PD-L1 (SP263) Assay as an in vitro diagnostic2 test for KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, to identify untreated and previously treated metastatic non-small cell lung cancer patients eligible for the immunotherapy. KEYTRUDA is marketed by Merck & Co., Inc., Kenilworth N.J., US, known as MSD outside the US and Canada.

Lung cancer remains the leading cause of cancer deaths, with an annual estimated 12.9 percent of all new cancer cases and nearly 1.6 million deaths worldwide. NSCLC accounts for approximately 85 percent of all lung cancer cases.4 During the past three decades, lung cancer has shown the least improvement in survival rates when compared with other cancers.5

The VENTANA PD-L1 (SP263) Assay is the only fully automated PD-L1 assay for KEYTRUDA to launch on Roche's BenchMark series of instruments. The launch should significantly increase patient access to PD-L1 testing given Roche's extensive global diagnostic instrument base.

"Roche first launched the VENTANA PD-L1 (SP263) Assay in September 2016 as a diagnostic test for previously treated metastatic NSCLC patients in countries accepting the CE mark. We are very pleased to expand its application to include patients being considered for KEYTRUDA immunotherapy as the first line of treatment," said Ann Costello, Head of Roche Tissue Diagnostics. "The assay provides new insights into possible treatment options for this potentially deadly disease."

Roche will continue to pursue regulatory approval for the VENTANA PD-L1 (SP263) Assay in other cancer indications and in other geographies. For more information, go to PDL1ihc.com.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
宝清县| 新巴尔虎左旗| 德保县| 阳东县| 濉溪县| 灵石县| 石渠县| 武义县| 日喀则市| 潜江市| 营口市| 禄丰县| 永康市| 拉萨市| 抚松县| 贵州省| 惠安县| 平昌县| 邢台县| 上饶县| 边坝县| 永和县| 确山县| 彰化市| 集贤县| 通山县| 梁平县| 永宁县| 泊头市| 嘉善县| 三门峡市| 湟中县| 舟山市| 聊城市| 三亚市| 堆龙德庆县| 锡林浩特市| 成武县| 化州市| 泾川县| 清水县|